Want to see AARD full AI Analyst Report?
Aardvark Therapeutics, Inc. (AARD) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ard-101 | Prader-Willi Syndrome, Hyperphagia In Prader-Willi Syndrome, Hyperphagia | Phase III | Recruiting | The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial | Sep 21, 2025 | ― |
| Ard-101 | Prader-Willi Syndrome, Hyperphagia | Phase III | Recruiting | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial | Feb 13, 2025 | ― |
| Low Dose Ard-501, High Dose Ard-501 | Autism Spectrum Disorder | Phase II | Completed | A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | Oct 20, 2023 | ― |
| Ard-101 | Obesity, Weight Gain, Bariatric Surgery | Phase II | Completed | Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery | Jan 03, 2022 | ― |
| Ard-101 | Prader-Willi Syndrome | Phase II | Completed | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | Nov 30, 2021 | ― |
| Ard-101 | Obesity | Phase II | Completed | Study to Evaluate ARD-101 in Adults With Obesity | Oct 19, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ard-101 | Phase III | Prader-Willi Syndrome, Hyperphagia In Prader-Willi Syndrome, Hyperphagia | Recruiting | The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial | Sep 21, 2025 | ― |
| Ard-101 | Phase III | Prader-Willi Syndrome, Hyperphagia | Recruiting | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial | Feb 13, 2025 | ― |
| Low Dose Ard-501, High Dose Ard-501 | Phase II | Autism Spectrum Disorder | Completed | A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | Oct 20, 2023 | ― |
| Ard-101 | Phase II | Obesity, Weight Gain, Bariatric Surgery | Completed | Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery | Jan 03, 2022 | ― |
| Ard-101 | Phase II | Prader-Willi Syndrome | Completed | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | Nov 30, 2021 | ― |
| Ard-101 | Phase II | Obesity | Completed | Study to Evaluate ARD-101 in Adults With Obesity | Oct 19, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Aardvark Therapeutics, Inc. (AARD) have in its pipeline
Aardvark Therapeutics, Inc. AARD is currently developing the following drugs: Ard-101, Low Dose Ard-501, High Dose Ard-501. These drug candidates are in various stages of clinical development as the company works toward FDA approval.